TY  - JOUR
T1  - PReexposure prophylaxis for hiv infection
AU  - Steinbrook R
Y1  - 2012/09/05
N1  - 10.1001/jama.2012.9885
JO  - JAMA
SP  - 865
EP  - 866
VL  - 308
IS  - 9
N2  - 
On July 16, 2012, the US Food and Drug Administration (FDA) approved a daily oral antiretroviral drug to reduce the risk of sexual acquisition of human immunodeficiency virus (HIV) infection by uninfected adults.1- 2 Emtricitabine/tenofovir disoproxil fumarate (marketed by Gilead as Truvada) contains 2 nucleoside analogue HIV-1 reverse transcriptase inhibitors. Initially approved in 2004 to treat HIV infection in combination with other antiretroviral medications in people 12 years of age and older, emtricitabine/tenofovir costs about $13 900 a year in the United States for a year of treatment.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.9885
UR  - http://dx.doi.org/10.1001/jama.2012.9885
ER  -